|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Markman M and Mekhail TM: Paclitaxel in
cancer therapy. Expert Opin Pharmacother. 3:755–766. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Richardson DL, Sill MW, Coleman RL, Sood
AK, Pearl ML, Kehoe SM, Carney ME, Hanjani P, Van Le L, Zhou XC, et
al: Paclitaxel with and without pazopanib for persistent or
recurrent ovarian cancer: A randomized clinical trial. JAMA Oncol.
4:196–202. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pignata S, Lorusso D, Scambia G, Sambataro
D, Tamberi S, Cinieri S, Mosconi AM, Orditura M, Brandes AA,
Arcangeli V, et al: Pazopanib plus weekly paclitaxel versus weekly
paclitaxel alone for platinum-resistant or platinum-refractory
advanced ovarian cancer (MITO 11): A randomised, open-label, phase
2 trial. Lancet Oncol. 16:561–568. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Browning L, Patel M, Bring Horvath E,
Tawara K and Jorcyk C: IL-6 and ovarian cancer: Inflammatory
cytokines in promotion of metastasis. Cancer Manag Res.
10:6685–6693. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Heo TH, Wahler J and Suh N: Potential
therapeutic implications of IL-6/IL-6R/gp130-targeting agents in
breast cancer. Oncotarget. 7:154602016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ernst M and Jenkins BJ: Acquiring
signalling specificity from the cytokine receptor gp130. Trends
Genet. 20:23–32. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rebouissou S, Amessou M, Couchy G, Poussin
K, Imbeaud S, Pilati C, Izard T, Balabaud C, Bioulac-Sage P and
Zucman-Rossi J: Frequent in-frame somatic deletions activate gp130
in inflammatory hepatocellular tumours. Nature. 457:200–204. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Murakami M, Kamimura D and Hirano T:
Pleiotropy and specificity: Insights from the interleukin 6 family
of cytokines. Immunity. 50:812–831. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ernst M and Putoczki TL: Molecular
pathways: IL11 as a tumor-promoting cytokine-translational
implications for cancers. Clin Cancer Res. 20:5579–5588. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rose-John S: Interleukin-6 family
cytokines. Cold Spring Harb Perspect Biol. 10:a0284152018.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bromberg J and Wang TC: Inflammation and
cancer: IL-6 and STAT3 complete the link. Cancer Cell. 15:79–80.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Haan C, Heinrich PC and Behrmann I:
Structural requirements of the interleukin-6 signal transducer
gp130 for its interaction with Janus kinase 1: The receptor is
crucial for kinase activation. Biochem J. 361:105–111. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Taher MY, Davies DM and Maher J: The role
of the interleukin (IL)-6/IL-6 receptor axis in cancer. Biochem Soc
Trans. 46:1449–1462. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Skiniotis G, Boulanger MJ, Garcia KC and
Walz T: Signaling conformations of the tall cytokine receptor gp130
when in complex with IL-6 and IL-6 receptor. Nat Struct Mol Biol.
12:545–551. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dijkgraaf EM, Welters MJ, Nortier JW, van
der Burg SH and Kroep JR: Interleukin-6/interleukin-6 receptor
pathway as a new therapy target in epithelial ovarian cancer. Curr
Pharm Des. 18:3816–3827. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Levy DE and Darnell JE Jr: Stats:
Transcriptional control and biological impact. Nat Rev Mol Cell
Biol. 3:651–662. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li H, Xiao H, Lin L, Jou D, Kumari V, Lin
J and Li C: Drug design targeting protein-protein interactions
(PPIs) using multiple ligand simultaneous docking (MLSD) and drug
repositioning: Discovery of raloxifene and bazedoxifene as novel
inhibitors of IL-6/GP130 interface. J Med Chem. 57:632–641. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fu S, Chen X, Lo HW and Lin J: Combined
bazedoxifene and paclitaxel treatments inhibit cell viability, cell
migration, colony formation, and tumor growth and induce apoptosis
in breast cancer. Cancer Lett. 448:11–19. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim L, Park S, Park H, Kim H and Heo TH:
Bazedoxifene, a GP130 inhibitor, modulates EMT signaling and
exhibits antitumor effects in HPV-positive cervical cancer. Int J
Mol Sci. 22:86932021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu X, Cao Y, Xiao H, Li C and Lin J:
Bazedoxifene as a novel GP130 inhibitor for pancreatic cancer
therapy. Mol Cancer Ther. 15:2609–2619. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tian J, Chen X, Fu S, Zhang R, Pan L, Cao
Y, Wu X, Xiao H, Lin HJ, Lo HW, et al: Bazedoxifene is a novel
IL-6/GP130 inhibitor for treating triple-negative breast cancer.
Breast Cancer Res Treat. 175:553–566. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wei J, Ma L, Lai YH, Zhang R, Li H, Li C
and Lin J: Correction to: Bazedoxifene as a novel GP130 inhibitor
for colon cancer therapy. J Exp Clin Cancer Res. 38:3742019.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hong SS, Choi JH, Lee SY, Park YH, Park
KY, Lee JY, Kim J, Gajulapati V, Goo JI, Singh S, et al: A novel
small-molecule inhibitor targeting the IL-6 receptor β subunit,
glycoprotein 130. J Immunol. 195:237–245. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Beaufort CM, Helmijr JC, Piskorz AM,
Hoogstraat M, Ruigrok-Ritstier K, Besselink N, Murtaza M, van IJcken
WF, Heine AA, Smid M, et al: Ovarian cancer cell line panel (OCCP):
Clinical importance of in vitro morphological subtypes. PLoS One.
9:e1039882014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fu W, Zhao P, Li H, Fu H, Liu X, Liu Y, Wu
J and Fu W: Bazedoxifene enhances paclitaxel efficacy to suppress
glioblastoma via altering Hippo/YAP pathway. J Cancer. 11:657–667.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chang Q, Daly L and Bromberg J: The IL-6
feed-forward loop: A driver of tumorigenesis. Semin Immunol.
26:48–53. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huang M, Page C, Reynolds RK and Lin J:
Constitutive activation of stat 3 oncogene product in human ovarian
carcinoma cells. Gynecol Oncol. 79:67–73. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Duan Z, Ames RY, Ryan M, Hornicek FJ,
Mankin H and Seiden MV: CDDO-Me, a synthetic triterpenoid, inhibits
expression of IL-6 and Stat3 phosphorylation in multi-drug
resistant ovarian cancer cells. Cancer Chemother Pharmacol.
63:681–689. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wolf J, Rose-John S and Garbers C:
Interleukin-6 and its receptors: A highly regulated and dynamic
system. Cytokine. 70:11–20. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xu S, Grande F, Garofalo A and Neamati N:
Discovery of a novel orally active small-molecule gp130 inhibitor
for the treatment of ovarian cancer. Mol Cancer Ther. 12:937–949.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Huang F, Tong X, Fu L and Zhang R:
Knockdown of STAT3 by shRNA inhibits the growth of CAOV3 ovarian
cancer cell line in vitro and in vivo. Acta Biochim Biophys Sin
(Shanghai). 40:519–525. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yu H, Kortylewski M and Pardoll D:
Crosstalk between cancer and immune cells: Role of STAT3 in the
tumour microenvironment. Nat Rev Immunol. 7:41–51. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hirano T, Ishihara K and Hibi M: Roles of
STAT3 in mediating the cell growth, differentiation and survival
signals relayed through the IL-6 family of cytokine receptors.
Oncogene. 19:2548–2556. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Evan GI and Vousden KH: Proliferation,
cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ling YH, Yang Y, Tornos C, Singh B and
Perez-Soler R: Paclitaxel-induced apoptosis is associated with
expression and activation of c-Mos gene product in human ovarian
carcinoma SKOV3 cells. Cancer Res. 58:3633–3640. 1998.PubMed/NCBI
|
|
37
|
Orr GA, Verdier-Pinard P, McDaid H and
Horwitz SB: Mechanisms of taxol resistance related to microtubules.
Oncogene. 22:7280–7295. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jones NA, Turner J, McIlwrath AJ, Brown R
and Dive C: Cisplatin-and paclitaxel-induced apoptosis of ovarian
carcinoma cells and the relationship between bax and bak
up-regulation and the functional status of p53. Mol Pharmacol.
53:819–826. 1998.PubMed/NCBI
|
|
39
|
Nielsen M, Kaestel CG, Eriksen K, Woetmann
A, Stokkedal T, Kaltoft K, Geisler C, Röpke C and Odum N:
Inhibition of constitutively activated Stat3 correlates with
altered Bcl-2/Bax expression and induction of apoptosis in mycosis
fungoides tumor cells. Leukemia. 13:735–738. 1999. View Article : Google Scholar : PubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBI
|
